Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: L-Theanine (γ-glutamylethylamide) augmentation to antipsychotic therapy ameliorates positive, activation, and anxiety symptoms in schizophrenia and schizoaffective disorder patients. This study examines the association between circulating levels of neurochemical indicators and the beneficial clinical effects of L-theanine augmentation. METHODS: Serum levels of neurochemical indicators such as brain-derived neurotrophic factor (BDNF), dehydroepiandrosterone (DHEA), its sulfate (DHEAS), cortisol, cholesterol, and insulin were monitored in 40 schizophrenia and schizoaffective disorder patients during an 8-week, double-blind, randomized, placebo-controlled trial with L-theanine (400 mg/d). Multiple regression analysis was applied for searching association between improvement in symptom scores and changes in circulating levels of neurochemical indicators for an 8-week trial. RESULTS: Regression models among L-theanine-treated patients indicate that circulating levels of BDNF and cortisol-to-DHEAS*100 molar ratio were significantly associated with the beneficial clinical effects of L-theanine augmentation. Variability of serum BDNF levels accounted for 26.2% of the total variance in reduction of dysphoric mood and 38.2% in anxiety scores. In addition, the changes in cortisol-to-DHEAS*100 molar ratio accounted for 30% to 34% of the variance in activation factor and dysphoric mood scores and for 15.9% in anxiety scores. Regression models among placebo-treated patients did not reach significant level. CONCLUSIONS: These preliminary results indicate that circulating BDNF and cortisol-to-DHEAS*100 molar ratio may be involved in the beneficial clinical effects of L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another publication [32] from the same research group, analysing a subset of 40 participants from the clinical trial referred above, observed improvements in circulating levels of brain-derived neurotrophic factor and cortisol to dehydroepiandrosterone sulfate ratio after L-theanine supplementation.”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [32]
In the citing paper
“Another publication [32] from the same research group, analysing a subset of 40 participants from the clinical trial referred above, observed improvements in circulating levels of brain-derived neurotrophic factor and cortisol to dehydroepiandrosterone sulfate ratio after L-theanine supplementation.”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [32]
In the citing paper
“The authors emphasized in both studies the beneficial effects of L-theanine alongside its safety and good tolerance at daily doses of 400 mg [25,32].”
From Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia (2019) · cites this paper as [32]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,050
Majewska, M. D. (1992) · Progress in Neurobiology · doi:10.1016/0301-0082(92)90025-a · Cited by 1,086
The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
Wolf, M. E. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00090-7 · Cited by 934
Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.11.002 · Cited by 769
BDNF in schizophrenia, depression and corresponding animal models
Angelucci, F., Brenè, S., & Mathé, A. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001637 · Cited by 548
Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it
Flood, J. F., Morley, J. E., & Roberts, E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1567 · Cited by 436
Empirical Assessment of the Factorial Structure of Clinical Symptoms in Schizophrenia
White, L., Harvey, P. D., Opler, L., & Lindenmayer, J. P. (1997) · Psychopathology · doi:10.1159/000285058 · Cited by 363
Medicinal Benefits of Green Tea: Part I. Review of Noncancer Health Benefits
Cooper, R., Morré, D. J., & Morré, D. M. (2005) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2005.11.521 · Cited by 360
Cited by
Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E., Breier, A., Shekhar, A., Amdur, R., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 397
Walker, E. F., Trotman, H. D., Pearce, B. D., Addington, J., Cadenhead, K. S., Cornblatt, B. A., Heinssen, R., Mathalon, D. H., Perkins, D. O., Seidman, L. J., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.016 · Cited by 269
Anxiety in Patients with Schizophrenia: Epidemiology and Management
Temmingh, H., & Stein, D. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0282-7 · Cited by 173
Brain foods - the role of diet in brain performance and health
Ekstrand, B., Scheers, N., Rasmussen, M. K., Young, J. F., Ross, A. B., & Landberg, R. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa091 · Cited by 101
Lardner, A. L. (2014) · Nutritional Neuroscience · doi:10.1179/1476830513y.0000000079 · Cited by 92
Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review
Arroll, M. A., Wilder, L., & James, N. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-91 · Cited by 82
de Assis, G. G., & Gasanov, E. V. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100784 · Cited by 63
Effect of l-theanine on glutamatergic function in patients with schizophrenia
Ota, M., Wakabayashi, C., Sato, N., Hori, H., Hattori, K., Teraishi, T., Ozawa, H., Okubo, T., & Kunugi, H. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.22 · Cited by 52
Sechi, S., Cerbo, A. D., Canello, S., Guidetti, G., Chiavolelli, F., Fiore, F., & Cocco, R. (2016) · Veterinary Record · doi:10.1136/vr.103865 · Cited by 63
Lopes Sakamoto, F., Metzker Pereira Ribeiro, R., Amador Bueno, A., & Oliveira Santos, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104395 · Cited by 49
Yoneda, Y., Kuramoto, N., & Kawada, K. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104505 · Cited by 39
Bulaj, G. W., Ahern, M., Kuhn, A. K., Judkins, Z., Bowen, R. C., & Chen, Y. (2016) · Current Clinical Pharmacology · doi:10.2174/1574884711666160603012237 · Cited by 44
Sanada, K., Zorrilla, E. P., Iwata, Y., Ampudia, C. B., Graff‐Guerrero, A., Martínez‐Cengotitabengoa, M., & González-Pinto, A. M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101766 · Cited by 38
Liberona, A., Jones, N., Zúñiga, K., Candia, V. A. G., Zelada, M. I., Hernán Silva, I., & Nieto, R. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011204 · Cited by 36
Wang, D., Cai, M., Wang, T., Zhao, G., Huang, J., Wang, H., Qian, F., Ho, C., & Wang, Y. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.04.001 · Cited by 28
Antiglucocorticoid and related treatments for psychosis
Garner, B., Phillips, L. J., Bendall, S., & Hetrick, S. E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006995.pub2 · Cited by 27
Investigational drugs for anxiety in patients with schizophrenia
Garay, R. P., Samalin, L., Hameg, A., & Llorca, P. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.987339 · Cited by 28
Cerbo, A. D., Sechi, S., Canello, S., Guidetti, G., Fiore, F., & Cocco, R. (2017) · Journal of Visualized Experiments · doi:10.3791/54878 · Cited by 34
Howells, F. M., Kingdon, D., & Baldwin, D. S. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2628 · Cited by 27
Moshfeghinia, R., Sanaei, E., Mostafavi, S., Assadian, K., Sanaei, A., & Ayano, G. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06285-y · Cited by 17
Wise, L. E., Premaratne, I. D., Gamage, T. F., Lichtman, A. H., Hughes, L. D., Harris, L. S., & Aceto, M. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.008 · Cited by 16
Selective upregulation by theanine of Slc38a1 expression in neural stem cell for brain wellness
Yoneda, Y., Kawada, K., & Kuramoto, N. (2020) · Molecules · doi:10.3390/molecules25020347 · Cited by 13
“The beneficial effectiveness was positively correlated with serum levels of brain-derived neurotrophic factor in schizophrenic and schizoaffective patients orally given theanine for eight weeks [74].”
BackgroundMorton, L. C., Paton, C. D., & Braakhuis, A. J. (2024) · Nutrients · doi:10.3390/nu16020233 · Cited by 13
L-Theanine Improves Locomotor Function in a Model of Multiple Sclerosis Mice.
Khosravi-Nezhad, S., Hassanpour, S., & Hesaraki, S. (2023) · PubMed Central · doi:10.22092/ari.2022.360066.2544 · Cited by 5
Neurobiological effects of theanine and its possible use in neurology and psychiatry
Ab, K. (2018) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2018118111118 · Cited by 7
Perrotta, C., Carnovale, C., Pozzi, M., Palma, C. D., Cervia, D., Nobile, M., & Clementi, E. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100061 · Cited by 4
Krzyściak, W., Szwajca, M., Śmierciak, N., Chrzan, R. M., Turek, A., Karcz, P., Bryll, A., Pilecki, M. W., Morava, É., Ligezka, A. N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56344-3 · Cited by 4
Behaviors observed in different live species depending on nutrition
Aydemir, E., & Topcan, A. (2022) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2022.15.2.0811 · Cited by 1
Ritsner, M. S. (2012) · Springer eBooks · doi:10.1007/978-94-007-5805-6_8 · Cited by 1
Self-citationGérolymos, C., Saddier, E., Boyer, L., & Fond, G. B. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03727-9 · Cited by 1
Metadata
- Authors
- Miodownik, C., Maayan, R., Ratner, Y., Lerner, V., Pintov, L., Mar, M., Weizman, A., & Ritsner, M. S.
- Affiliations
- Ben-Gurion University of the Negev (IL)
- Sha'ar Menashe Mental Health Center (IL)
- Tel Aviv University (IL)
- Technion – Israel Institute of Technology (IL)
- Corresponding author
- Miodownik, Chanoch
- Lerner, Vladimir
- Venue
- Clinical Neuropharmacology
- Published
- 2011-07
- Volume
- 34
- Issue
- 4
- Pages
- 155-160
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W1975395689
- Cited by
- 31
- References
- 59
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- theanine, antipsychotic augmentation, schizophrenia, schizoaffective disorder, brain-derived neurotrophic factor, cortisol, dehydroepiandrosterone sulfate, neurochemical markers, dysphoric mood, anxiety symptoms, positive symptoms
- MeSH terms
- Adult, Algorithms, Anxiety, Double-Blind Method, Drug Therapy, Combination, Female, Glutamates, Humans, Hydrocortisone, Male, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Antipsychotic Agents, Biomarkers, Brain-Derived Neurotrophic Factor, Dehydroepiandrosterone Sulfate, Mood Disorders, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.